PDGF receptor kinase inhibitors for the treatment of restenosis

Alexander Levitzki

doi:10.1016/j.cardiores.2004.08.008

PDGF receptor kinase inhibitors for the treatment of restenosis

Alexander Levitzki^*

^*Corresponding author for this work

Alexander Silberman Institute of Life Sciences

Research output: Contribution to journal › Review article › peer-review

82 Scopus citations

Abstract

The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury.

Original language	English
Pages (from-to)	581-586
Number of pages	6
Journal	Cardiovascular Research
Volume	65
Issue number	3
DOIs	https://doi.org/10.1016/j.cardiores.2004.08.008
State	Published - 15 Feb 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
PDGF
Restenosis
Tyrphostins

Access to Document

10.1016/j.cardiores.2004.08.008

Cite this

@article{d4348d8e68814cf4aaa97499d7a09ec8,

title = "PDGF receptor kinase inhibitors for the treatment of restenosis",

abstract = "The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury.",

keywords = "Cancer, PDGF, Restenosis, Tyrphostins",

author = "Alexander Levitzki",

year = "2005",

month = feb,

day = "15",

doi = "10.1016/j.cardiores.2004.08.008",

language = "אנגלית",

volume = "65",

pages = "581--586",

journal = "Cardiovascular Research",

issn = "0008-6363",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - PDGF receptor kinase inhibitors for the treatment of restenosis

AU - Levitzki, Alexander

PY - 2005/2/15

Y1 - 2005/2/15

N2 - The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury.

AB - The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury.

KW - Cancer

KW - PDGF

KW - Restenosis

KW - Tyrphostins

UR - https://www.scopus.com/pages/publications/12344249427

U2 - 10.1016/j.cardiores.2004.08.008

DO - 10.1016/j.cardiores.2004.08.008

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 15664384

AN - SCOPUS:12344249427

SN - 0008-6363

VL - 65

SP - 581

EP - 586

JO - Cardiovascular Research

JF - Cardiovascular Research

IS - 3

ER -

PDGF receptor kinase inhibitors for the treatment of restenosis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this